Certara launches Cardiac Safety Simulator to determine arrhythmia risk for drug candidates

Based on an in-silico model of human ventricular heart cells, Certara’s Cardiac Safety Simulator (CSS) helps sponsors to assess arrhythmia risk before a new drug candidate enters clinical trials and determine safe drug doses for specific patient populations.

| 1 min read

Certara

To continue reading this article, subscribe for FREE to

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Internal Medicine

Certara launches Cardiac Safety Simulator to determine arrhythmia risk for drug candidates

Here are some related topics that may interest you:

Subscribe to our eNewsletters

Sponsored